LUCD (Lucid Diagnostics) Notes Receivable: $0.00 Mil (As of Mar. 2026)


LUCD Lucid Diagnostics Inc LUCD
26 GF Score
Price $1.07
GF Value $0.81
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lucid Diagnostics Notes Receivable?

Lucid Diagnostics LUCD +4.85% 26 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates LUCD with a GF Score™ of 26/100 and a GF Value™ of $0.81 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Lucid Diagnostics's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Lucid Diagnostics Notes Receivable Related Terms

Lucid Diagnostics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Lucid Diagnostics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucid Diagnostics Notes Receivable Chart

Lucid Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Lucid Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LUCD
26GF Score
Lucid Diagnostics Inc LUCD
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lucid Diagnostics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Lucid Diagnostics (LUCD) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Lucid Diagnostics and its competitors.
Is Lucid Diagnostics' Notes Receivable too high?
Lucid Diagnostics' current Notes Receivable is $0.00 Mil. Overall, Lucid Diagnostics has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' Notes Receivable compare to TLSI and INFU?
Lucid Diagnostics' Notes Receivable of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Lucid Diagnostics and its competitors. Lucid Diagnostics's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.81, compared to a current price of $1.07 — trading 31.5% above its estimated fair value. The current Notes Receivable is $0.00 Mil. Lucid Diagnostics' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lucid Diagnostics (LUCD) Overvalued in 2026?

Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued. The current stock price of $1.07 is trading 31.5% above its estimated GF Value™ of $0.81. GuruFocus considers Lucid Diagnostics to be Significantly Overvalued.

Key valuation signals for LUCD:

  • Notes Receivable: $0.00 Mil
  • GF Value™: $0.81 vs. price of $1.07 (31.5% above fair value)
  • GF Score™: 26/100 with 5 warning signs

No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lucid Diagnostics Business Description

Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
26GF Score

Get the complete analysis for LUCD

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.07
Price
$0.81
GF Value